Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (30)	9/12/2003 1:04:52 PM
From: gg cox	Read Replies (1) \| Respond to of 66

IMI to trade on American Stock Exchange beginning September 17 TORONTO, Sep 12, 2003 (Canada NewsWire via COMTEX) -- (Canada NewsWire) Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI, AMEX:IME) announced today that its common stock will trade on the American Stock Exchange (AMEX), under the ticker symbol IME, beginning September 17, 2003. The company's stock will also continue to trade on The Toronto Stock Exchange under the symbol IMI. "Listing IMI stock on a U.S. exchange opens the door to new investors in what is obviously a vital market," said Dr. Brent Norton, IMI President and CEO. "As we achieve more milestones in the development and commercialization of our products, we believe it will be important to provide U.S. investors a means of responding to the news and participating in our growth." "We are committed to maintaining a frequent and reliable dialogue with our shareholders and the broader investment communities in both the U.S. and Canada. And we are committed to meeting and exceeding regulatory requirements in both jurisdictions, ensuring maximum disclosure and transparency for our shareholders," said Dr. Norton. About IMI IMI is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The company's lead product is Cholesterol 1,2,3(TM), the world's first non-invasive cholesterol test system. IMI is also developing a suite of screening tests for cancer, including ColorectAlert(TM) for colorectal cancer, LungAlert(TM) for lung cancer, and a new test for early-stage breast cancer. For further information, please visit the company's web site at www.imimedical.com.